JATT Acquisition (JATT) Competitors $1.30 0.00 (0.00%) As of 07/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. FBRX, ZURA, ENTX, IPA, ABVC, VRCA, IGMS, IMUX, CABA, and EPIXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Forte Biosciences (FBRX), Zura Bio (ZURA), Entera Bio (ENTX), ImmunoPrecise Antibodies (IPA), ABVC BioPharma (ABVC), Verrica Pharmaceuticals (VRCA), IGM Biosciences (IGMS), Immunic (IMUX), Cabaletta Bio (CABA), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors Forte Biosciences Zura Bio Entera Bio ImmunoPrecise Antibodies ABVC BioPharma Verrica Pharmaceuticals IGM Biosciences Immunic Cabaletta Bio ESSA Pharma JATT Acquisition (NYSE:JATT) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media favor JATT or FBRX? In the previous week, Forte Biosciences had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Forte Biosciences and 0 mentions for JATT Acquisition. Forte Biosciences' average media sentiment score of 1.29 beat JATT Acquisition's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Forte Biosciences Positive Is JATT or FBRX more profitable? JATT Acquisition's return on equity of -49.58% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Forte Biosciences N/A -149.15%-114.25% Do analysts rate JATT or FBRX? Forte Biosciences has a consensus price target of $61.00, indicating a potential upside of 531.86%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Forte Biosciences is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in JATT or FBRX? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, JATT or FBRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AForte BiosciencesN/AN/A-$35.48M-$16.29-0.59 SummaryForte Biosciences beats JATT Acquisition on 6 of the 10 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$22.43M$269.39M$5.56B$20.60BDividend YieldN/AN/A4.23%3.65%P/E RatioN/AN/A28.6127.20Price / SalesN/A430.44437.4953.52Price / Cash27.0822.4436.0222.28Price / Book-2.459.668.184.58Net Income$6.85M-$110.10M$3.23B$995.22M7 Day Performance8.33%-0.30%-0.25%-1.09%1 Month Performance8.33%12.26%5.40%3.25%1 Year Performance-64.77%16.96%26.35%6.97% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.30flatN/A-84.1%$22.43MN/A0.003High Trading VolumeFBRXForte Biosciences3.4985 of 5 stars$12.48flat$61.00+388.8%+42,163.0%$82.16MN/A-0.775Gap DownZURAZura Bio3.0761 of 5 stars$1.35+12.5%$14.33+961.7%-64.8%$82.05MN/A-1.933High Trading VolumeENTXEntera Bio2.5778 of 5 stars$1.83+2.8%$10.00+446.4%+0.5%$80.90M$180K-7.0420Gap UpIPAImmunoPrecise Antibodies2.9946 of 5 stars$1.92+9.1%$4.00+108.3%+86.3%$80.55M$18.16M-1.6680Upcoming EarningsABVCABVC BioPharma0.3946 of 5 stars$4.68-1.3%N/A+349.6%$80.50M$508.38K-36.0030News CoverageHigh Trading VolumeVRCAVerrica Pharmaceuticals4.4536 of 5 stars$0.82-4.9%$8.00+875.6%-90.5%$79.72M$7.18M-0.6840High Trading VolumeIGMSIGM Biosciences4.6326 of 5 stars$1.35+1.5%$5.50+307.4%-87.0%$79.50M$2.68M-0.41190Positive NewsHigh Trading VolumeIMUXImmunic2.4827 of 5 stars$0.81-2.8%$11.60+1,339.6%-38.7%$79.45MN/A-0.6670CABACabaletta Bio2.7515 of 5 stars$1.71+13.2%$14.43+743.8%-79.1%$76.62MN/A-0.6750News CoverageEPIXESSA Pharma1.0573 of 5 stars$1.71flat$2.00+17.0%-66.7%$75.90MN/A-2.7150 Related Companies and Tools Related Companies FBRX Alternatives ZURA Alternatives ENTX Alternatives IPA Alternatives ABVC Alternatives VRCA Alternatives IGMS Alternatives IMUX Alternatives CABA Alternatives EPIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
